MEDICENNA THERAPEUTICS CORP (MDNA.CA) Fundamental Analysis & Valuation

TSX:MDNA • CA58490H1073

Current stock price

0.59 CAD
0 (0%)
Last:

This MDNA.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MDNA.CA Profitability Analysis

1.1 Basic Checks

  • MDNA had negative earnings in the past year.
  • In the past year MDNA has reported a negative cash flow from operations.
  • MDNA had negative earnings in each of the past 5 years.
  • MDNA had a negative operating cash flow in each of the past 5 years.
MDNA.CA Yearly Net Income VS EBIT VS OCF VS FCFMDNA.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • MDNA has a Return On Assets of -99.41%. This is comparable to the rest of the industry: MDNA outperforms 43.48% of its industry peers.
  • The Return On Equity of MDNA (-209.08%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -99.41%
ROE -209.08%
ROIC N/A
ROA(3y)-67.42%
ROA(5y)-67.89%
ROE(3y)-195.49%
ROE(5y)-148.03%
ROIC(3y)N/A
ROIC(5y)N/A
MDNA.CA Yearly ROA, ROE, ROICMDNA.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • MDNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDNA.CA Yearly Profit, Operating, Gross MarginsMDNA.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MDNA.CA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, MDNA has more shares outstanding
  • The number of shares outstanding for MDNA has been increased compared to 5 years ago.
  • The debt/assets ratio for MDNA is higher compared to a year ago.
MDNA.CA Yearly Shares OutstandingMDNA.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
MDNA.CA Yearly Total Debt VS Total AssetsMDNA.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • MDNA has an Altman-Z score of -14.77. This is a bad value and indicates that MDNA is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -14.77, MDNA perfoms like the industry average, outperforming 43.48% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that MDNA is not too dependend on debt financing.
  • MDNA has a better Debt to Equity ratio (0.01) than 82.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -14.77
ROIC/WACCN/A
WACCN/A
MDNA.CA Yearly LT Debt VS Equity VS FCFMDNA.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • MDNA has a Current Ratio of 2.68. This indicates that MDNA is financially healthy and has no problem in meeting its short term obligations.
  • MDNA has a Current ratio of 2.68. This is in the better half of the industry: MDNA outperforms 69.57% of its industry peers.
  • A Quick Ratio of 2.68 indicates that MDNA has no problem at all paying its short term obligations.
  • MDNA's Quick ratio of 2.68 is fine compared to the rest of the industry. MDNA outperforms 69.57% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.68
MDNA.CA Yearly Current Assets VS Current LiabilitesMDNA.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MDNA.CA Growth Analysis

3.1 Past

  • MDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.46%, which is quite impressive.
EPS 1Y (TTM)59.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, MDNA will show a very negative growth in Earnings Per Share. The EPS will decrease by -48.34% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-47.34%
EPS Next 2Y-60.04%
EPS Next 3Y-48.34%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDNA.CA Yearly Revenue VS EstimatesMDNA.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 20M 40M 60M 80M
MDNA.CA Yearly EPS VS EstimatesMDNA.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.1 -0.2 -0.3 -0.4

More info and screens

Find the best growth stocksShow best growing peers

0

4. MDNA.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • MDNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDNA.CA Price Earnings VS Forward Price EarningsMDNA.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDNA.CA Per share dataMDNA.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

  • A cheap valuation may be justified as MDNA's earnings are expected to decrease with -48.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-60.04%
EPS Next 3Y-48.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDNA.CA Dividend Analysis

5.1 Amount

  • MDNA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDNA.CA Fundamentals: All Metrics, Ratios and Statistics

MEDICENNA THERAPEUTICS CORP

TSX:MDNA (4/22/2026, 7:00:00 PM)

0.59

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)06-23
Inst Owners6.32%
Inst Owner ChangeN/A
Ins Owners14.4%
Ins Owner ChangeN/A
Market Cap49.22M
Revenue(TTM)N/A
Net Income(TTM)-12.99M
Analysts82
Price Target3.09 (423.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.71%
Min EPS beat(2)7.12%
Max EPS beat(2)18.3%
EPS beat(4)3
Avg EPS beat(4)35.11%
Min EPS beat(4)-17.65%
Max EPS beat(4)132.68%
EPS beat(8)5
Avg EPS beat(8)-10.3%
EPS beat(12)9
Avg EPS beat(12)1.21%
EPS beat(16)13
Avg EPS beat(16)12.08%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.69%
EPS NY rev (1m)-1.57%
EPS NY rev (3m)3.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.92
P/tB 7.98
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -99.41%
ROE -209.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.42%
ROA(5y)-67.89%
ROE(3y)-195.49%
ROE(5y)-148.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.68
Quick Ratio 2.68
Altman-Z -14.77
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y-47.34%
EPS Next 2Y-60.04%
EPS Next 3Y-48.34%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.58%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICENNA THERAPEUTICS CORP / MDNA.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MEDICENNA THERAPEUTICS CORP?

ChartMill assigns a fundamental rating of 1 / 10 to MDNA.CA.


Can you provide the valuation status for MEDICENNA THERAPEUTICS CORP?

ChartMill assigns a valuation rating of 0 / 10 to MEDICENNA THERAPEUTICS CORP (MDNA.CA). This can be considered as Overvalued.


How profitable is MEDICENNA THERAPEUTICS CORP (MDNA.CA) stock?

MEDICENNA THERAPEUTICS CORP (MDNA.CA) has a profitability rating of 1 / 10.


What is the financial health of MEDICENNA THERAPEUTICS CORP (MDNA.CA) stock?

The financial health rating of MEDICENNA THERAPEUTICS CORP (MDNA.CA) is 4 / 10.